Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared a post by The Breast Friends Podcast on X, adding:
“Thanks to OncotypeDX, we’re now able to spare unnecessary chemo to thousands of women with ER+ breast cancer.
HER2DX promises to take the HER2+ subtype to a similar era of increased treatment precision, enabling to modulate chemotherapy to the risk and sensitivity of the tumor.”
Quoting The Breast Friends Podcaston’s post:
“Think Oncotype—but for HER2+ disease.
Jason A. Mouabbi and Paolo Tarantino
Watch on YouTube.
Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox, and Amazon Music.”
Inside The Breast Friends Podcast With Paolo Tarantino and Jason Mouabbi
